SCHEMBL6571604

SCHEMBL6571604

O=C(NCCCn1ccnc1)c1ccc(Cl)cc1

nearest known ligand 0.93

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.84
NPC1 O15118 1/20 0.78
POLB P06746 1/20 0.75
MEN1 O00255 1/20 0.74
KMT2A Q03164 1/20 0.74
CYP1A2 P05177 1/20 0.71
CYP3A4 P08684 1/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C9 P11712 1/20 0.71
CYP2C19 P33261 1/20 0.71
ALDH1A1 P00352 2/20 0.70
MAPT P10636 1/20 0.70
TSHR P16473 1/20 0.70
KDM4E B2RXH2 1/20 0.69
HTT P42858 1/20 0.69
CYP19A1 P11511 1/20 0.67
NAMPT P43490 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9715141 0.95 SMN1; SMN2 (0.77) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL21098369 0.93 SMN1; SMN2 (0.89) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL4484066 0.88 SMN1; SMN2 (0.80) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL4770380 0.87 SMN1; SMN2 (0.78) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL5257694 0.87 SMN1; SMN2 (0.78) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL13211944 0.87 SMN1; SMN2 (0.78) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL95881 0.87 SMN1; SMN2 (0.78) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL16359671 0.87 SMN1; SMN2 (0.78) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL1775216 0.86 SMN1; SMN2 (0.82) SMN1; SMN2NPC1POLBMEN1KMT2A
SCHEMBL10931952 0.85 ALDH1A1 (0.75) SMN1; SMN2NPC1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4568687-A THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS AMERICAN CYANAMID COMPANY (US) 1986-02-04 US claimed
EP-1420009-A2 Novel amino acid derivatives with improved multi-drug resistance activity Vertex Pharmaceuticals Incorporated (US) 2004-05-19 EP disclosed
EP-0797567-B1 NOVEL AMINO ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY VERTEX PHARMA (US) 2004-02-11 EP disclosed
EP-0946190-B1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE OUTGROWTH VERTEX PHARMA (US) 2003-09-24 EP disclosed
US-6284778-B1 NEUROTROPHIC AGENT VERTEX PHARMACEUTICALS INCORPORATED 2001-09-04 US disclosed
US-6172086-B1 TREATING PARKINSON*S DISEASE, ALZHIEMER*S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS AND OTHER NERVOUS SYSTEM DISORDERS VERTEX PHARMACEUTICALS INCORPORATED 2001-01-09 US disclosed
EP-0946190-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS Vertex Pharmaceuticals Incorporated (US) 1999-10-06 EP disclosed
US-5840736-A PEPTIDES FOR NERVE GROWTH VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-11-24 US disclosed
WO-1998020891-A1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-05-22 WO disclosed
US-5543423-A USED IN MULTI-DRUG RESISTANCE CANCER THERAPY VERTEX PHARMACEUTICALS, INCORPORATED (US) 1996-08-06 US disclosed
EP-0117462-A2 N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides AMERICAN CYANAMID COMPANY (US) 1984-09-05 EP disclosed